🔗 Share this article

Given that America undertakes unprecedented changes to its immunization guidelines, one figure has surfaced in a surprising turn: Tracy Beth Høeg, a Danish American sports physician and epidemiologist who rose to prominence by casting doubt on Covid shots throughout the pandemic and has focused upon possible deaths after COVID-19 immunization in her brief position at the Food and Drug Administration.

Planned Overhauls to Childhood Vaccine Program

Agency leaders were set to unveil sweeping revisions to the childhood immunization program recently, bringing the US with the Danish national calendar, sources say – a significant shift that would put the US at odds with many the global community with no evidence for improved outcomes. The announcement has been pushed back until the coming year.

Rather than Vinay Prasad, Dr. Høeg is set to address the audience at the meeting. She was just designated acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth individual to lead the division this calendar year.

A Shift at the Regulatory Body

The acting appointment might represent a tighter collaboration between the drug and biologics centers as Høeg and Prasad strengthen their influence at the FDA – and it suggests a renewed priority upon dismantling previously authorized immunizations at the FDA.

Høeg has frequently advocated for discontinuing certain childhood immunization guidelines in the US in order to be more like Denmark's approach, a nation with universal health coverage and a citizenry approximately the size of the state of Wisconsin.

In her initial comments, she has persisted in emphasizing on vaccination policy – typically the purview of Dr. Prasad, chief of the FDA’s CBER – rather than pharmaceutical oversight.

Questions Over Qualifications

The appointee has no apparent experience in pharmaceutical research, oversight or administrative roles, which has been customary for former directors of the CBER. She has been employed at the FDA as a key advisor to the agency head and the vaccine center since earlier this year.

“It seems she lacks to have the necessary background” for overseeing the pharmaceutical oversight division, remarked Dr. Jonathan Howard. “She’s never run a randomized controlled trial. She has no expertise in managing a major agency. She has no expertise in drug approvals.”

Former heads of CBER would “grasp laws and regulations and the science of drug development”, said a former acting FDA commissioner. “Frankly, she has not acquired the kind of background that prior appointees who headed the center have had.”

CDER has an vast portfolio at the FDA, the former commissioner pointed out.

“Everybody just focuses on the novel medication approvals, but the off-patent medication office authorizes numerous generic drugs. There’s a biosimilars program, OTC medication office and more, and all of those must be looked after,” Woodcock noted. “The responsibility you neglect, that is precisely what that I always told people is going to bite you.”

Furthermore, a significant leadership element to the job, which manages more than 5,000 personnel. “It is a massive leadership role, if you perform it correctly,” Woodcock concluded.

Response and Controversial Policies

When asked about inquiries about Dr. Høeg's credentials and whether this appointment represents greater collaboration among agency officials on vaccines, a press secretary responded that the “inquiries are based on inaccurate presumptions”.

“This background aligns with the functions of her position,” the official stated, pointing to the period Høeg spent counseling the agency head on “drug safety and approval science, including computerized risk analysis and vaccine surveillance”.

As the temporary head, Høeg takes over the commissioner’s recently launched priority voucher program, a contentious rapid therapy clearance system that allegedly worried her preceding directors. “By what process are these medications being picked for this expedited pathway? Who takes the decisions?” Dr. Howard questioned. “There’s a lot of lack of transparency happening at the agency right now.”

In general, he stated, “the agency appears to be shifting towards less stringent regulations of all drugs, with the exception of immunizations.”

Documented History on Vaccines

With vaccines, Høeg has a clearer, if troubling, track record, Howard observe. She authored a analysis using non-validated crowd-sourced reports to assess the rate of myocarditis following Covid immunization. She advised the state of Florida chief medical officer Dr. Joseph Ladapo, who was said to have modified findings to suggest COVID-19 vaccinations are riskier than they are.

Included in her “policy goals” for the new administration featured revising regulations for novel immunizations and halting “unnecessary” vaccines, she said post-election on a online show. At the FDA, Høeg has according to sources suggested excluding teenage boys from receiving COVID-19 vaccinations.

“She is an complete true believer who commences with her beliefs and reverse-engineers to fit the evidence in a extremely deceptive, fraudulent fashion,” Dr. Howard argued.

Gaining Influence and a “Push for Payback”

Dr. Høeg aligned with other contrarians, {like|